Drugs / PEG-rhG-GSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06563869 | Feb 2024 → Nov 2025 overdue | esophageal squamous cell carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-rhG-GSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06563869 ↗ |
| Modality | Protein / enzyme biologic | “Polyethylene glycolylated recombinant human granulocyte stimulating factor” NCT06563869 ↗ |